SG11201903236SA - Lasofoxifene treatment of er+ breast cancer - Google Patents
Lasofoxifene treatment of er+ breast cancerInfo
- Publication number
- SG11201903236SA SG11201903236SA SG11201903236SA SG11201903236SA SG11201903236SA SG 11201903236S A SG11201903236S A SG 11201903236SA SG 11201903236S A SG11201903236S A SG 11201903236SA SG 11201903236S A SG11201903236S A SG 11201903236SA SG 11201903236S A SG11201903236S A SG 11201903236SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- erwin
- durham
- suite
- road
- Prior art date
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title abstract 4
- 229960002367 lasofoxifene Drugs 0.000 title abstract 4
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 title abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 206010064571 Gene mutation Diseases 0.000 abstract 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111 IOU 0 11101 HOE 3E1 0 011101111111111111110 MO 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/093484 Al 24 May 2018 (24.05.2018) W I PO I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) Applicant: DUKE UNIVERSITY [US/US]; 2812 Erwin (72) Inventors: ANDREANO, Kaitlyn; c/o Duke University, International Patent Classification: NC 27705 (US). GAILLARD, Stephanie, L.; c/o Duke A61K 31/00 (2006.01) A61P 35/00 (2006.01) University, 2812 Erwin Road, Suite 306, Box 90083, A61K 31/40 (2006.01) A61K 45/06 (2006.01) Durham, NC 27705 (US). A61P 35/04 (2006.01) (74) Agent: SUN, Danqiong et al.; Fenwick & West LLP, Sili- International Application Number: con Valley Center, 801 California Street, Mountain View, PCT/US2017/055970 CA 94041 (US). International Filing Date: (81) Designated States (unless otherwise indicated, for every 10 October 2017 (10.10.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/406,859 11 October 2016 (11.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/457,759 10 February 2017 (10.02.2017) US May 2017 (05.05.2017) US 62/502,299 05 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Road, Suite 306, Box 90083, Durham, NC 27705 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, 2812 Erwin Road, Suite 306, Box 90083, Durham, NC GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 27705 (US). CHANG, Ching-yi; c/o Duke University, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 2812 Erwin Road, Suite 306, Box 90083, Durham, NC TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 27705 (US). MCDONNELL, Donald, P.; c/o Duke Uni- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, versity, 2812 Erwin Road, Suite 306, Box 90083, Durham, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, _ = = Title: LASOFOXIFENE TREATMENT 1.5 m _ ce co N ct — E o z 0.0 : The disclosure provides lasofoxifene, a pharmaceutically acceptable Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine (54) M FIG. ei Estrogen _1 1.0 OF ER+ BREAST CANCER Lasofoxifene women with an effective amount includes the detection of the resistant ER cancers. + = = = = = —0— WT —o— Y537N Y537S - V - Y537C —0—D538G = — = %.- 0.5 • • y = _ = — = — 1-1 iv o r © p o p (57) C of • v 0 -12 -10 -8 Log [M] 2B methods for treating estrogen receptor positive (ER ) cancer in + salt thereof, or a prodrug thereof. The disclosure also o [Continued on next page] WO 2018/093484 Al 111111111111110111011111111111011111010111110111111100111111111111111111011110111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406859P | 2016-10-11 | 2016-10-11 | |
| US201762457759P | 2017-02-10 | 2017-02-10 | |
| US201762502299P | 2017-05-05 | 2017-05-05 | |
| PCT/US2017/055970 WO2018093484A1 (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903236SA true SG11201903236SA (en) | 2019-05-30 |
Family
ID=60186386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913951YA SG10201913951YA (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
| SG11201903236SA SG11201903236SA (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913951YA SG10201913951YA (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20190231718A1 (en) |
| EP (2) | EP4035662A1 (en) |
| JP (4) | JP6892151B2 (en) |
| KR (5) | KR102285453B1 (en) |
| CN (3) | CN112353796A (en) |
| AU (2) | AU2017360365B2 (en) |
| BR (1) | BR112019007254A2 (en) |
| CA (1) | CA3040266A1 (en) |
| DK (1) | DK3525774T3 (en) |
| ES (1) | ES2909576T3 (en) |
| IL (2) | IL284875B (en) |
| MX (2) | MX2019004184A (en) |
| NZ (1) | NZ752443A (en) |
| PL (1) | PL3525774T3 (en) |
| PT (1) | PT3525774T (en) |
| RU (1) | RU2019114079A (en) |
| SG (2) | SG10201913951YA (en) |
| TW (2) | TWI790672B (en) |
| WO (2) | WO2018071440A1 (en) |
| ZA (1) | ZA201902454B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| ES2909576T3 (en) | 2016-10-11 | 2022-05-09 | Univ Duke | Lasofoxifene treatment of ER+ breast cancer |
| CN112261937B (en) * | 2018-04-10 | 2023-11-14 | 杜克大学 | Lasofoxifene treatment of breast cancer |
| CN114306245A (en) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | Pharmaceutical composition of amorphous solid dispersion and preparation method thereof |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023230222A1 (en) * | 2022-05-25 | 2023-11-30 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (en) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| HN1996000101A (en) | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| WO1999065498A1 (en) | 1998-06-19 | 1999-12-23 | Senju Pharmaceutical Co., Ltd. | Agents for relieving side effects of adrenal cortex hormone |
| YU26700A (en) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Process for cis -1-(2-(4-(6-metoxy-2-pheniyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoksy)etil)pyrrolidine |
| US6436977B1 (en) | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| CO5271697A1 (en) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE |
| CA2395730A1 (en) | 2000-01-28 | 2001-08-02 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
| DE10039199A1 (en) | 2000-08-10 | 2002-02-21 | Schering Ag | Combination preparations from an ERß selective estrogen and a SERM or antiestrogen |
| AU2001283139A1 (en) | 2000-08-11 | 2002-02-25 | Wyeth | Method of treating estrogen receptor positive carcinoma |
| AU2002235348A1 (en) | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| DK1487790T3 (en) | 2002-03-28 | 2010-05-10 | Pfizer Prod Inc | Purified lasofoxifene and method of opening racemic lasofoxifene by recrystallization |
| PA8576201A1 (en) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO |
| RS20070166A (en) | 2004-10-20 | 2008-09-29 | Endorecherche Inc., | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator... |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| US20110015134A1 (en) | 2007-04-16 | 2011-01-20 | Retsky Michael W | Method of treatment for early stage cancer |
| CZ2007373A3 (en) | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Process for preparing lasofoxifene |
| WO2009126662A1 (en) | 2008-04-08 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator |
| US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| EP2239570A1 (en) * | 2009-04-10 | 2010-10-13 | PamGene B.V. | Method for determining the estrogen receptor status of breast cancer |
| WO2012024255A2 (en) | 2010-08-16 | 2012-02-23 | Duke University | Camkk-beta as a target for treating cancer |
| US20120052508A1 (en) * | 2010-08-27 | 2012-03-01 | Rutgers, The State University Of New Jersey | Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies |
| EA201300996A1 (en) | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | USE OF EGFR FAMILY RECEPTOR INHIBITORS IN THE TREATMENT OF THE BREAST-GROWTH CANCER |
| US20140079665A1 (en) | 2011-05-18 | 2014-03-20 | Merck Sharp & Dohme Corp. | Therapeutic anti-igf1r combinations |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| MX2014007198A (en) | 2011-12-16 | 2014-10-13 | Olema Pharmaceuticals Inc | Novel benzopyran compounds, compositions and uses thereof. |
| US20160038506A1 (en) | 2012-02-14 | 2016-02-11 | Repros Therapeutics Inc. | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof |
| US9204286B1 (en) | 2013-03-15 | 2015-12-01 | Sprint Communications Company L.P. | System and method of branding and labeling a mobile device |
| CA2941161A1 (en) * | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| MA39741A (en) | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| SI3122426T1 (en) | 2014-03-28 | 2023-04-28 | Duke University | Treating breast cancer using selective estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CN104208069A (en) | 2014-05-08 | 2014-12-17 | 上海市计划生育科学研究所 | Anordrin composition and disease treatment method using the same |
| RU2017116070A (en) | 2014-11-07 | 2018-12-07 | Липоксен Текнолоджис Лимитед | METHOD FOR TREATING PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCER |
| US20180049999A1 (en) | 2015-04-14 | 2018-02-22 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
| EP4039253A1 (en) * | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
| US20190231743A1 (en) | 2016-10-11 | 2019-08-01 | Sermonix Pharmaceuticals, Llc | Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies |
| ES2909576T3 (en) | 2016-10-11 | 2022-05-09 | Univ Duke | Lasofoxifene treatment of ER+ breast cancer |
| EP3568132A4 (en) | 2017-01-10 | 2020-09-09 | Wang, Wei | Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment |
-
2017
- 2017-10-10 ES ES17791239T patent/ES2909576T3/en active Active
- 2017-10-10 NZ NZ752443A patent/NZ752443A/en unknown
- 2017-10-10 KR KR1020197013405A patent/KR102285453B1/en active IP Right Grant
- 2017-10-10 AU AU2017360365A patent/AU2017360365B2/en active Active
- 2017-10-10 JP JP2019540308A patent/JP6892151B2/en active Active
- 2017-10-10 WO PCT/US2017/055974 patent/WO2018071440A1/en active Application Filing
- 2017-10-10 CA CA3040266A patent/CA3040266A1/en active Pending
- 2017-10-10 US US16/341,033 patent/US20190231718A1/en not_active Abandoned
- 2017-10-10 MX MX2019004184A patent/MX2019004184A/en unknown
- 2017-10-10 RU RU2019114079A patent/RU2019114079A/en unknown
- 2017-10-10 CN CN202011320148.5A patent/CN112353796A/en active Pending
- 2017-10-10 US US15/729,320 patent/US20180098963A1/en not_active Abandoned
- 2017-10-10 KR KR1020227037620A patent/KR102623130B1/en active IP Right Grant
- 2017-10-10 EP EP21215433.0A patent/EP4035662A1/en active Pending
- 2017-10-10 KR KR1020237008605A patent/KR102531354B1/en active IP Right Grant
- 2017-10-10 CN CN202110143863.4A patent/CN112933082A/en active Pending
- 2017-10-10 IL IL284875A patent/IL284875B/en unknown
- 2017-10-10 BR BR112019007254A patent/BR112019007254A2/en active Search and Examination
- 2017-10-10 KR KR1020217023829A patent/KR102462433B1/en active IP Right Grant
- 2017-10-10 EP EP17791239.1A patent/EP3525774B1/en active Active
- 2017-10-10 SG SG10201913951YA patent/SG10201913951YA/en unknown
- 2017-10-10 CN CN201780073528.3A patent/CN110099680B/en active Active
- 2017-10-10 PT PT177912391T patent/PT3525774T/en unknown
- 2017-10-10 WO PCT/US2017/055970 patent/WO2018093484A1/en unknown
- 2017-10-10 KR KR1020247000452A patent/KR20240007720A/en active Application Filing
- 2017-10-10 SG SG11201903236SA patent/SG11201903236SA/en unknown
- 2017-10-10 DK DK17791239.1T patent/DK3525774T3/en active
- 2017-10-10 PL PL17791239T patent/PL3525774T3/en unknown
- 2017-10-11 TW TW110124571A patent/TWI790672B/en active
- 2017-10-11 TW TW106134805A patent/TWI729227B/en active
-
2018
- 2018-03-28 US US15/939,218 patent/US10258604B2/en active Active
-
2019
- 2019-02-01 US US16/265,109 patent/US10905659B2/en active Active
- 2019-04-10 MX MX2021013911A patent/MX2021013911A/en unknown
- 2019-04-10 IL IL265938A patent/IL265938B/en unknown
- 2019-04-17 ZA ZA2019/02454A patent/ZA201902454B/en unknown
-
2020
- 2020-10-16 US US17/073,253 patent/US20210361596A1/en not_active Abandoned
-
2021
- 2021-02-16 JP JP2021022514A patent/JP7247241B2/en active Active
-
2022
- 2022-10-09 AU AU2022246480A patent/AU2022246480A1/en active Pending
-
2023
- 2023-01-13 JP JP2023003699A patent/JP7418052B2/en active Active
- 2023-03-30 US US18/193,207 patent/US20230233490A1/en active Pending
- 2023-12-26 JP JP2023219161A patent/JP2024026527A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |